A Phase 2 interventional study of Prednisolone and Dexamethasone in B Lymphoblastic Leukemia, sponsored by National University Hospital, Singapore. Recruiting at 3 sites in 2 countries. Open to participants aged Up to 40 Years. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by National University Hospital, Singapore · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 5 open to participants now, 10 under way, 2 of them phase 3. Dasatinib · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2020, is one of 19 in phase 2, and was the 41st registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →5 of the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
Hyoung Jin Kang · Sites in Korea, Republic of
Ages 1–19
University of Chicago · Sites in United States
Ages 18+
By country, each count listing its studies:
Dasatinib: first FDA approval 2006 (SPRYCEL), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: Up to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 25 · Phase 3 7 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 51 across the 41 interventional studies. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 42 have an industry lead sponsor. The 10 most frequent:
National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.
National University Hospital, Singapore has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02494882Memorial Sloan Kettering Cancer CenterAdding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing dasatinib in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia (B-ALL) in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy.
This is a multicenter open-label phase II study involving children and young adult (\< 41 years old) who are newly diagnosed with B-ALL and treatment naïve. There will be 3 parallel cohorts whose risk to be stratified based upon leukemia genetics profiles and patient's treatment response:
All drugs being used are commercially available chemotherapy drugs. There will be no novel chemotherapeutic agent without marketing authorization being tested in this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has been diagnosed with B-lineage ALL as evidenced by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. No anthracycline throughout the treatment. 2. CNS consolidation using "Capizzi type" low dose methotrexate (LDMTX) x 2 courses to replace pre-existing high dose methotrexate (HDMTX) 2.5g #3/4
Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine
Those with CD20 ≥ 20% expression on diagnostic blasts by flow immunophenotyping will receive additional dose of rituximab on day 1 of each delayed intensification (DI) phases: phase III (2 courses) and V (1 course) for total 3 infusions
Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine · Drug: Rituximab · Drug: Doxorubicin
Provisional HR patients will be offered CAR-T cell immunotherapy or HSCT
Drug: Prednisolone · Drug: Dexamethasone · Drug: Vincristine · Drug: Methotrexate · Drug: L-Asparaginase · Drug: Pegylated asparaginase · Drug: Erwinase · Drug: Dasatinib · Drug: Imatinib · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Mercaptopurine · Drug: Thioguanine · Drug: Doxorubicin · Drug: Fludarabine
Oral
Oral
Intravenous
Oral/ intrathecal/intravenous/subcutaneous
Intramuscular
Intravenous
Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
Intravenous
Subcutaneous/ Intravenous
Oral
Oral
Intravenous
Intravenous
Intravenous
Overall survival (OS)
OS is calculated from the date of diagnosis to the date of last follow-up or any death
Time frame: 5 years from diagnosis
Event free survival (EFS)
EFS will be calculated from the date of diagnosis of ALL to date of last follow-up or to the first event, including relapse, resistant disease, second malignancy and death
Time frame: 5 years from diagnosis
Cumulative incidence (CI) of relapse for all treated cohorts
Time frame: 5 years from diagnosis
Cumulative incidence (CI) of therapy-related mortality (TRM) for all treated subjects
Time frame: 5 years from diagnosis
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Mar 2030, 120 months after the start.
Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 120 months is above that.
Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dasatinib · Imatinib · Rituximab · Doxorubicin · Fludarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
National University Hospital, Singapore →